The Form 4 filing, an SEC report of insider share trades, covers sales on November 16–17, 2026. It was filed on November 18. The report lists QVT Financial LP as “Other, Director by Deputization.”
Roivant Sciences (ROIV) is a healthcare company in the biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | sell |
| Transaction Count | 7 |
| Shares Transacted | 1,381,762 |
| Price | $38.75 |
| Total Transaction Value | $53,536,738.01 |
| Insider | |
| Ticker Symbol | ROIV |
| Company | Roivant Sciences Ltd. |
| Insider Name | QVT Financial LP |
| Insider Title | Other, Director by Deputization |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under SEC transaction code S. QVT Financial LP reported seven sale transactions.
What was the average price of the transaction?
The average sale price was $38.75 per share, rounded to the nearest cent. Individual prices for the seven sales were not included in the available details.
How did this transaction affect the insider's holdings?
The sales reduced the reported holding by 1,381,762 shares, leaving zero shares afterward. The shares sold made up 100.00% of the shares held before these sales. That zero balance applies to the holding reported here.
What's the total transaction value?
The seven sales had a total value of $53,536,738.01. This total covers all 1,381,762 shares reported sold.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. The filing’s footnote text was not provided, so any further terms or explanations in those notes remain unknown. The available details do not explain why the shares were sold.
For research purposes only; not investment advice.